Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Mallinckrodt
Medtronic
McKinsey
McKesson

Last Updated: April 9, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for TAK-981


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for TAK-981?

TAK-981 is an investigational drug.

There have been 323 clinical trials for TAK-981. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2016.

The most common disease conditions in clinical trials are Diabetes Mellitus, Hypertension, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and National Cancer Institute (NCI).

There are three US patents protecting this investigational drug and twenty-six international patents.

Recent Clinical Trials for TAK-981
TitleSponsorPhase
Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Participants With Persistent/Chronic Primary Immune ThrombocytopeniaMillennium Pharmaceuticals, Inc.Phase 2
Efficiency of Methotrexate and Tofacitinib in Mild and Moderate PatientsShanghai Zhongshan HospitalPhase 4
A Pharmacokinetic and Safety Study of TAK-925 in Participants With Idiopathic HypersomniaMillennium Pharmaceuticals, Inc.Phase 1

See all TAK-981 clinical trials

Clinical Trial Summary for TAK-981

Top disease conditions for TAK-981
Top clinical trial sponsors for TAK-981

See all TAK-981 clinical trials

US Patents for TAK-981

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
TAK-981   Start Trial Heteroaryl compounds useful as inhibitors of sumo activating enzyme Millennium Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
TAK-981   Start Trial Heteroaryl compounds useful as inhibitors of SUMO activating enzyme Millennium Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
TAK-981   Start Trial Heteroaryl compounds useful as inhibitors of SUMO activating enzyme Millennium Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Medtronic
Moodys
Colorcon
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.